Literature DB >> 1396753

Influence of vaccination schedules and host factors on antibody response following hepatitis B vaccination.

G Hess1, V Hingst, J Cseke, H L Bock, R Clemens.   

Abstract

In a prospective multicentre trial, the influence of schedule, compliance, age, sex and weight on the antibody response to hepatitis B vaccination was investigated. Comparison of the vaccination schedules 0, 1, 6 months (group 1; n = 143) and 0, 1, 2, 12 months (group 2; n = 141) was performed in months 3, 7 and 12. In addition, the antibody response was compared one month after the third and one and six months after the last vaccination. Seroprotection rates (anti-HBs greater than 10 IU/l) and antibody titres, given as geometric means (GMTs), were higher in group 1 at month 12 as well as one month after completion of three immunizations. More vaccinees of group 2, however, showed seroprotection at month 3 with higher GMTs. In addition, GMTs in group 2 were higher both one month and six months after the last vaccine dose. Determination of parallel corrected correlation factors demonstrated that age was the most important single factor, followed by body weight and sex. However, no more than 3% of the variation in the GMT can be explained by the influence of age. Due to decreased compliance with the four-dose schedule with a drop-out rate of approximately 10% of the vaccinees, the total percentage of initial vaccinees who in the end developed protective antibody levels was higher in the 0, 1, 6 months schedule. Thus, it can be concluded that subjects likely to comply will benefit from the 0, 1, 2, 12 months schedule as more rapid protection is obtained and the higher antibody levels after the booster vaccination at month 12 provide longer protection. However, vaccinees whose compliance might be questionable over a period of 12 months, should be selected for the vaccination 0, 1, 6 months schedule as compliance is at a higher level over this period and advantage can be taken of the booster effect of the third dose given in month 6.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1396753     DOI: 10.1007/bf01962073

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  21 in total

1.  Active immunization of homosexual men using a recombinant hepatitis B vaccine.

Authors:  G Hess; S Rossol; R Voth; D Cheatham-Speth; R Clemens; K H Meyer zum Büschenfelde
Journal:  J Med Virol       Date:  1989-12       Impact factor: 2.327

2.  Four-year experience with a recombinant hepatitis B vaccine.

Authors:  W Jilg; M Schmidt; F Deinhardt
Journal:  Infection       Date:  1989 Mar-Apr       Impact factor: 3.553

3.  Overview of clinical studies with hepatitis B vaccine made by recombinant DNA.

Authors:  B A Zajac; D J West; W J McAleer; E M Scolnick
Journal:  J Infect       Date:  1986-07       Impact factor: 6.072

4.  Duration of immunity after hepatitis B vaccination: efficacy of low-dose booster vaccine.

Authors:  M M Horowitz; W B Ershler; W P McKinney; R J Battiola
Journal:  Ann Intern Med       Date:  1988-02       Impact factor: 25.391

5.  Humoral and cellular immune responses by normal individuals to hepatitis B surface antigen vaccination.

Authors:  L G Filion; R Saginur; N Szczerbak
Journal:  Clin Exp Immunol       Date:  1988-03       Impact factor: 4.330

6.  Non-responsiveness to hepatitis-B vaccination: revaccination and immunogenetic typing.

Authors:  A Krämer; D Herth; H J von Keyserlingk; W D Ludwig; H Hampl; D Sommer; E G Hahn; E O Riecken
Journal:  Klin Wochenschr       Date:  1988-08-01

Review 7.  Recombinant versus plasma-derived hepatitis B vaccines: issues of safety, immunogenicity and cost-effectiveness.

Authors:  J Stephenne
Journal:  Vaccine       Date:  1988-08       Impact factor: 3.641

8.  Effect of anatomic injection site, age and smoking on the immune response to hepatitis B vaccination.

Authors:  F E Shaw; H A Guess; J M Roets; F E Mohr; P J Coleman; E J Mandel; R R Roehm; W S Talley; S C Hadler
Journal:  Vaccine       Date:  1989-10       Impact factor: 3.641

9.  Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine.

Authors:  F E André
Journal:  Vaccine       Date:  1990-03       Impact factor: 3.641

10.  Impaired responsiveness of homosexual men with HIV antibodies to plasma derived hepatitis B vaccine.

Authors:  C A Carne; I V Weller; J Waite; M Briggs; F Pearce; M W Adler; R S Tedder
Journal:  Br Med J (Clin Res Ed)       Date:  1987-04-04
View more
  9 in total

Review 1.  Factors That Influence the Immune Response to Vaccination.

Authors:  Petra Zimmermann; Nigel Curtis
Journal:  Clin Microbiol Rev       Date:  2019-03-13       Impact factor: 26.132

2.  Randomized trial of the immunogenicity and safety of the Hepatitis B vaccine given in an accelerated schedule coadministered with the human papillomavirus type 16/18 AS04-adjuvanted cervical cancer vaccine.

Authors:  Geert Leroux-Roels; Edwige Haelterman; Cathy Maes; Jack Levy; Fien De Boever; Laurent Licini; Marie-Pierre David; Kurt Dobbelaere; Dominique Descamps
Journal:  Clin Vaccine Immunol       Date:  2011-07-06

3.  Sex influences immune responses to viruses, and efficacy of prophylaxis and treatments for viral diseases.

Authors:  Sabra L Klein
Journal:  Bioessays       Date:  2012-09-26       Impact factor: 4.345

4.  Hepatitis B vaccination schedules in genitourinary medicine clinics.

Authors:  D Asboe; P Rice; A de Ruiter; J S Bingham
Journal:  Genitourin Med       Date:  1996-06

Review 5.  The Xs and Y of immune responses to viral vaccines.

Authors:  Sabra L Klein; Anne Jedlicka; Andrew Pekosz
Journal:  Lancet Infect Dis       Date:  2010-05       Impact factor: 71.421

6.  Comparison of Accelerated and Standard Hepatitis B Vaccination Schedules in High-Risk Healthy Adults: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Hui Jin; Zhaoying Tan; Xuefeng Zhang; Bei Wang; Yueyuan Zhao; Pei Liu
Journal:  PLoS One       Date:  2015-07-21       Impact factor: 3.240

Review 7.  Determinants of effective vaccine coverage in low and middle-income countries: a systematic review and interpretive synthesis.

Authors:  David E Phillips; Joseph L Dieleman; Stephen S Lim; Jessica Shearer
Journal:  BMC Health Serv Res       Date:  2017-09-26       Impact factor: 2.655

Review 8.  Impact of sex and gender on COVID-19 outcomes in Europe.

Authors:  Catherine Gebhard; Vera Regitz-Zagrosek; Hannelore K Neuhauser; Rosemary Morgan; Sabra L Klein
Journal:  Biol Sex Differ       Date:  2020-05-25       Impact factor: 5.027

9.  Timing of primary three-dose hepatitis B vaccination and postvaccination serologic testing among a large cohort of healthy adults.

Authors:  Özgür M Koc; Eva van Oorschot; Lloyd Brandts; Astrid Oude Lashof
Journal:  J Med Virol       Date:  2022-05-17       Impact factor: 20.693

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.